PMID- 20858564
OWN - NLM
STAT- MEDLINE
DCOM- 20110303
LR  - 20211020
IS  - 1878-5905 (Electronic)
IS  - 0142-9612 (Print)
IS  - 0142-9612 (Linking)
VI  - 32
IP  - 2
DP  - 2011 Jan
TI  - The use of micropatterning to control smooth muscle myosin heavy chain expression 
      and limit the response to transforming growth factor beta1 in vascular smooth muscle 
      cells.
PG  - 410-8
LID - 10.1016/j.biomaterials.2010.08.105 [doi]
AB  - In the healthy artery, contractile vascular smooth muscle cells (VSMCs) have an 
      elongated shape and are highly aligned but transition to a synthetic phenotype in 
      culture, while additionally becoming well spread and randomly organized. Thus, 
      controlling VSMC phenotype is a challenge in tissue engineering. In this study, 
      we investigated the effects of micropatterning on contractile protein expression 
      in VSMCs at low and high passage and in the presence of transforming growth 
      factor beta 1 (TGFbeta1). Micropatterning led to significantly decreased cell area, 
      increased elongation, and increased alignment compared to non-patterned VSMCs 
      independent of passage number. In the presence of serum, micropatterning led to 
      increased smooth muscle myosin heavy chain (SM-MHC) and alpha-actin expression in low 
      passage VSMCs, but had no effect on high passage VSMCs. Micropatterning was as 
      effective as TGFbeta1 in up-regulating SM-MHC at low passage; however, 
      micropatterning limited VSMC response to TGFbeta1 at both low and high passage. 
      Investigation of TGFbeta receptor 1 revealed higher expression in non-patterned 
      VSMCs compared to patterned at high passage. Our studies demonstrate that 
      micropatterning is an important regulator of SM-MHC expression in contractile 
      VSMCs and that it may provide a mechanism for phenotype stabilization in the 
      presence of growth factors.
CI  - Copyright (c) 2010 Elsevier Ltd. All rights reserved.
FAU - Williams, Corin
AU  - Williams C
AD  - Department of Biomedical Engineering, Boston University, Boston, MA 02215, USA.
FAU - Brown, Xin Q
AU  - Brown XQ
FAU - Bartolak-Suki, Erzsebet
AU  - Bartolak-Suki E
FAU - Ma, Hongwei
AU  - Ma H
FAU - Chilkoti, Ashutosh
AU  - Chilkoti A
FAU - Wong, Joyce Y
AU  - Wong JY
LA  - eng
GR  - R01 HL072900/HL/NHLBI NIH HHS/United States
GR  - R01 HL072900-06/HL/NHLBI NIH HHS/United States
GR  - R01 HL072900-08/HL/NHLBI NIH HHS/United States
GR  - R01 HL72900/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20100919
PL  - Netherlands
TA  - Biomaterials
JT  - Biomaterials
JID - 8100316
RN  - 0 (Polymers)
RN  - 0 (Transforming Growth Factor beta1)
RN  - EC 3.6.4.1 (Myosin Heavy Chains)
SB  - IM
MH  - Animals
MH  - Blotting, Western
MH  - Cell Culture Techniques
MH  - Cell Shape/*drug effects
MH  - Male
MH  - Muscle, Smooth, Vascular/*cytology
MH  - Myocytes, Smooth Muscle/*drug effects/*metabolism
MH  - Myosin Heavy Chains/*metabolism
MH  - Polymers/chemistry
MH  - Rabbits
MH  - Tissue Engineering/methods
MH  - Transforming Growth Factor beta1/*pharmacology
PMC - PMC2991379
MID - NIHMS234982
EDAT- 2010/09/23 06:00
MHDA- 2011/03/04 06:00
PMCR- 2012/01/01
CRDT- 2010/09/23 06:00
PHST- 2010/08/19 00:00 [received]
PHST- 2010/08/29 00:00 [accepted]
PHST- 2010/09/23 06:00 [entrez]
PHST- 2010/09/23 06:00 [pubmed]
PHST- 2011/03/04 06:00 [medline]
PHST- 2012/01/01 00:00 [pmc-release]
AID - S0142-9612(10)01143-9 [pii]
AID - 10.1016/j.biomaterials.2010.08.105 [doi]
PST - ppublish
SO  - Biomaterials. 2011 Jan;32(2):410-8. doi: 10.1016/j.biomaterials.2010.08.105. Epub 
      2010 Sep 19.